Skip to main content
    B

    Bristol-Myers Squibb Company (BMY)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $62.93
    -0.50 (-0.79%)

    Market Cap: $128.63B

    Last updated: Nov 17, 2026 at 4:37 PM ET

    Bristol-Myers Squibb Company (BMY) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Bristol-Myers Squibb Company (BMY) has a market cap of $128.63B and an enterprise value of $161.94B. Its dividend yield is 4.00%.

    Total Valuation

    Enterprise value is 25.89% above the market cap, as debt exceeds cash.

    Market Cap$128.63B
    Enterprise Value$161.94B
    Latest price (Nov 17, 2026)$62.93

    Key Dates

    The next earnings report is expected on Feb 3, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Oct 2, 2026.

    Next Earnings DateFeb 3, 2027 (expected)
    Last Earnings DateOct 29, 2026
    Last Ex-Dividend DateOct 2, 2026
    Last Payment DateNov 2, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.07% in the quarter ended Sep 30, 2026 and grew 0.39% a year over 2 years.

    Shares Outstanding2.04B
    Shares Change (YoY)+0.41%
    Shares Change (QoQ)+0.07%
    Share Count Growth (2Y CAGR)+0.39%

    Valuation Ratios

    Sales and book value multiples are 2.6x and 5.5x. Its year-end P/E ranged from 6.9x to 49.6x from 2016 to 2025.

    P/E Ratio10.1x
    Forward P/E9.6x
    P/S Ratio2.6x
    Forward P/S2.6x
    P/B Ratio5.5x
    P/FCF Ratio13.9x
    P/OCF Ratio12.1x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 11.5x EBITDA and 17.4x free cash flow.

    EV / Earnings17.5x
    EV / Sales3.2x
    EV / EBITDA11.5x
    EV / EBIT14.3x
    EV / FCF17.4x

    Price Statistics

    The stock is up 32.31% over 52 weeks and trades 2.18% above its 50-day average.

    Beta (1Y)0.23
    52-Week Change+32.31%
    1-Month Change+5.32%
    3-Month Change-3.74%
    6-Month Change+12.14%
    5-Year Change+6.99%
    10-Year Change+22.73%
    Total Return (1Y)+37.61%
    Total Return (3Y CAGR)+10.94%
    Total Return (5Y CAGR)+4.66%
    Return vs SPY (1Y)+25.17%
    Max Drawdown (1Y)-15.91%
    Max Drawdown (3Y)-30.71%
    Sharpe Ratio (1Y)1.15
    Correlation with SPY (1Y)0.12
    50-Day Average$61.59
    200-Day Average$59.63
    52-Week Range$43.34 to $67.94
    RSI (14 Days)53.8
    Average Volume (20 Days)10.04M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.59x current liabilities, and total debt is 1.83x shareholder equity.

    Current Ratio1.59x
    Quick Ratio1.44x
    Debt / Equity1.83x
    Debt / EBITDA3.04x
    Debt / FCF4.62x

    Returns and Efficiency

    Return on invested capital is 13.95% over the last 12 months, against a 5-year average of 5.55%.

    Return on Equity (ROE)39.48%
    Return on Assets (ROA)10.41%
    Return on Invested Capital (ROIC)13.95%
    Return on Capital Employed (ROCE)16.19%
    ROE (5Y Average)10.15%
    ROA (5Y Average)3.92%
    ROIC (5Y Average)5.55%
    Asset Turnover0.54x
    Inventory Turnover6.78x
    Receivables Turnover4.72x
    Cash Conversion Cycle44 days

    Taxes

    Income tax took 18.43% of pretax income over the last 12 months.

    Income Tax (TTM)$2.09B
    Effective Tax Rate18.43%

    Scores

    BMY has an Altman Z-Score of 2.65, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 8 of 9, in the strong band of 8 or 9.

    Altman Z-Score2.65
    Altman Z ZoneGrey
    Piotroski F-Score8 of 9
    Piotroski StrengthStrong

    Income Statement

    Revenue of $50.03B over the last 12 months is up 4.16% from the 12 months before.

    Revenue$50.03B
    Revenue Growth (YoY)+4.16%
    Gross Profit$31.60B
    Operating Income$11.56B
    Pretax Income$11.33B
    Net Income$9.24B
    EBITDA$14.12B
    EBIT$11.33B
    Reported EPS (TTM)$6.23

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 26.36% of the $88.77B in total assets.

    Cash and Equivalents$9.57B
    Total Debt$42.88B
    Net Debt$33.30B
    Net Debt Per Share$16.29
    Working Capital$11.01B
    Shareholder Equity$23.40B
    Book Value Per Share$11.45
    Tangible Book Value-$15.27B
    Total Assets$88.77B
    Total Liabilities$65.37B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.37B of capital spending, operating cash flow left $9.29B of free cash flow.

    Operating Cash Flow$10.65B
    Capital Expenditures$1.37B
    Free Cash Flow$9.29B
    FCF Per Share$4.55
    Depreciation and Amortization$2.79B
    Dividends Paid$5.12B

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 23.10%, against a 5-year average of 11.06%.

    Gross Margin63.16%
    Operating Margin23.10%
    Pretax Margin22.65%
    Net Margin18.47%
    EBITDA Margin28.23%
    EBIT Margin22.65%
    FCF Margin18.56%
    Gross Margin (5Y Average)66.66%
    Operating Margin (5Y Average)11.06%
    Net Margin (5Y Average)8.58%

    Growth

    Revenue grew 1.45% a year over 3 years, and EPS fell 7.22% a year.

    Revenue Growth (3Y CAGR)+1.45%
    Revenue Growth (5Y CAGR)+2.54%
    EPS Growth (3Y CAGR)-7.22%
    EPS Growth (5Y CAGR)-0.92%
    FCF Growth (3Y CAGR)+2.44%
    FCF Growth (5Y CAGR)-0.69%
    Operating Income Growth (3Y CAGR)+6.46%

    Revenue and profit by year

    Dividends and Yields

    BMY pays out 48.36% of earnings as dividends.

    Dividend Per Share (Annual)$2.52
    Dividend Yield4.00%
    Payment ScheduleQuarterly
    Dividend Growth (3Y CAGR)+4.71%
    Dividend Growth (5Y CAGR)+1.61%
    Payout Ratio48.36%
    FCF Payout Ratio55.13%
    Earnings Yield9.90%
    FCF Yield7.22%
    Shareholder Yield3.98%

    Full dividend history

    Stock Splits

    The last split was a 2-for-1 forward split on Mar 1, 1999.

    Last Split DateMar 1, 1999
    Split TypeForward split
    Split Ratio2:1

    Peer Position

    Against 9 similar companies, BMY has the 9th highest P/E.

    P/E Ratio10.1x vs 21.3x median
    P/S Ratio2.6x vs 4.9x median
    ROIC13.95% vs 13.48% median
    Revenue Growth (Trailing 4 Quarters, YoY)+4.16% vs +6.13% median
    Dividend Yield4.00% vs 2.37% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 0.63% and EPS growth at 4.37% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+0.63%
    EPS Growth Forecast (2Y CAGR)+4.37%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About BMY

    What is BMY's market cap?

    Bristol-Myers Squibb Company has a market cap of $128.63B. Its enterprise value, which adds debt and subtracts cash, is $161.94B.

    What is BMY's P/E ratio?

    Bristol-Myers Squibb Company has a trailing P/E ratio of 10.1x and a forward P/E of 9.6x.

    How many shares of BMY are outstanding?

    Bristol-Myers Squibb Company has 2.04B shares outstanding. The count is up 0.41% from a year earlier.

    Does BMY pay a dividend?

    Yes. Bristol-Myers Squibb Company pays $2.52 a share a year, a dividend yield of 4.00%.

    How much debt does BMY have?

    Bristol-Myers Squibb Company has $42.88B of total debt and $9.57B of cash and equivalents, a net debt position of $33.30B.